[1]王润泽,王建文.视网膜母细胞瘤免疫治疗研究进展[J].眼科新进展,2021,41(9):883-886.[doi:10.13389/j.cnki.rao.2021.0185]
　WANG Runze,WANG Jianwen.Progress in immunotherapy of retinoblastoma[J].Recent Advances in Ophthalmology,2021,41(9):883-886.[doi:10.13389/j.cnki.rao.2021.0185]
点击复制

视网膜母细胞瘤免疫治疗研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年9期
页码:
883-886
栏目:
文献综述
出版日期:
2021-09-05

文章信息/Info

Title:
Progress in immunotherapy of retinoblastoma
作者:
王润泽; 王建文
150000　黑龙江省哈尔滨市，哈尔滨医科大学附属第一医院眼科
Author(s):
WANG Runze; WANG Jianwen
Department of Ophthalmology,the First Affiliated Hospital of Harbin Medical University,Harbin 150000,Heilongjiang Province，China
关键词:
视网膜母细胞瘤; 免疫治疗; 免疫检查点抑制剂; 过继免疫疗法
Keywords:
retinoblastoma;  immunotherapy;  immunocheckpoint inhibitors;  adoptive immunotherapy
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0185
文献标志码:
A
摘要:
视网膜母细胞瘤（RB）作为一种儿童最常见的恶性肿瘤，其治疗方式一直备受关注。目前，虽然RB已成功采用一系列保守治疗方式来保留眼球和保存视功能，但由于RB可通过视神经扩散到中枢神经系统，并通过巩膜、眶骨的淋巴和血液循环进行远处转移。在这种情况下，RB的多数治疗方式的治疗效果均不佳。目前需要一种新的RB治疗方式，不仅能够更有效地抑制肿瘤生长，同时也能控制肿瘤的远处转移。免疫治疗能使正常组织的损伤最小化，更具有特异性，且可以防止随后的肿瘤复发，对于治疗RB具有很大的应用前景。本文将对RB免疫治疗最新进展进行综述。
Abstract:
Retinoblastoma (RB), as one of the most common malignant tumors in children, has been well concerned for its treatment. Although a series of conservative methods have been successfully preserved the eyeball and visual function in RB patients, it can spread to the central nervous system through the optic nerve, and cause distant metastases through the sclera, the lymph nodes of the orbital bone, and the blood circulation. Therefore, most of current therapeutic strategies do not yield a satisfactory efficacy on RB. A novel therapeutic strategy for RB is urgently needed to effectively control tumor growth and prevent distant metastasis. Immunotherapy is a highly specific treatment that minimizes the damage to normal tissues, and prevents subsequent recurrence, which is promising in the treatment of RB, and is being increasingly applied in clinical practices. This study aims to review the latest progress of immunotherapy for RB.

参考文献/References:

［1］　WANG Y F,KUNDA P E,LIN J W,WANG H,CHEN X M,LIU Q L,et al.Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells,have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells［J］.Oncol Rep,2013,29(5):1841-1850.
［2］　LYBAERT L,VERMAELEN K,DE GEEST B G,NUHN L.Immunoengineering through cancer vaccines:a personalized and multi-step vaccine approach towards precise cancer immunity［J］.J Controll Release,2018,289:125-145.
［3］　CHEN X,KUNDA P E,LIN J,ZHOU M,HUANG J,ZHANG H.SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma［J］.J Cancer Res Clin Oncol,2018,144(4):675-684.
［4］　WANG H,WEI F,LI H,JI X,LI S,CHEN X.Combination of oncolytic adenovirus and endostatin inhibits human retinoblastomain an in vivo mouse model［J］.Int J Mol Med,2013,31(2):377-385.
［5］　SINGH L,SINGH M K,RIZVI M A,BAKHSHI S,MEEL R,LOMI N,et al.Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma［J］.Cancer Immunol Immunother,2020,69(11) :1087-1099.
［6］　WANG Y F,KUNDA P E,LIN J W,WANG H,CHEN X M,LIU Q L,et al.Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells,have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells［J］.Oncol Rep,2013,29(5):1841-1850.
［7］　REARDON D A,WUCHERPFENNIG K W,FREEMAN G,WU C J,CHIOCCA E A,WEN P Y,et al.An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma［J］.Expert Rev Vaccines,2013,12(6):597-615.
［8］　LI F,KITAJIMA S,KOHNO S,YOSHIDA A,TANGE S,SASAKI S,et al.Retinoblastoma inactivation induces a protumoral microenvironment via enhanced CCL2 secretion［J］.Cancer Res,2019,79(15):3903-3915.
［9］　PATSOUKIS N,SARI D,BOUSSIOTIS V A.PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A ［J］.Cell Cycle,2012,11(23):4305-4309.
［10］　PATSOUKIS N,BROWN J,PETKOVA V,LIU F,LI L,BOUSSIOTIS V A.Selective effects of PD-1 on AKT and RAS pathways regulate molecular components of the cell cycle and inhibit T cell proliferation［J］.Sci Signal,2012,5(230):ra46.
［11］　RYU J I,HAN M H,CHEONG J H,KIM J M,KIM C H.Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas［J］.Immunotherapy,2017,9(5):411-421.
［12］　QIAN H,WANG H,GUAN X,YI Z,MA F.Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer:a meta-analysis［J］.Anticancer Drugs,2016,27(5):433-438.
［13］　KONDO T,IMURA Y,CHIKUMA S,HIBINO S,OMATA-MISE S.Generation and application of human induced-stem cell memory T (iT SCM ) cells for adoptive immunotherapy［J］.Cancer Sci,2018,109(7):2130-2140.
［14］　LIN H,LI Q,WANG O,RAUCH J,HARM B,VILJOEN H J,et al.Automated expansion of primary human T cells in scalable and cell-friendly hydrogel microtubes for adoptive immunotherapy［J］.Adv Healthc Mater,2018,7(15):1701297.
［15］　ANDERSCH L,RADKE J,KLAUS A,SCHWIEBERT S,WINKLER A,SCHUMANN E,et al.CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing［J］.BMC Cancer,2019,19(1):895.
［16］　SPRING L,BARDIA A,MODI S.Targeting the cyclin D-cyclin-dependent kinase (CDK)4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer:rationale,current status,and future directions［J］.Discov Med,2016,21(113):65-74.
［17］　LI C,QI L,BELLAIL A C,HAO C,LIU T.PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis［J］.Oncol Lett,2014,7(5):1673-1678.
［18］　CAO J,ZHU Z,WANG H,NICHOLS T C,LUI G Y L,DENG S,et al.Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer［J］.Oncogene,2019,38(21):4125-4141.
［19］　SOBHANI N,D’ANGELO A,PITTACOLO M,ROVIELLO G,MICCOLI A,CORONA S P,et al.Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer ［J］.Cells,2019,8(4):321.
［20］　ZHANG J,BU X,WANG H,ZHU Y,GENG Y,NIHIRA N T,et al.Author correction:cyclin D-CDK4 kinase destabilizes PD-L1 via cullin-3-SPOP to control cancer immune surveillance［J］.Nature,2019,571(7766):E10.
［21］　PERNAS S,TOLANEY S M,WINER E P,GOEL S.CDK4/6 inhibition in breast cancer:current practice and future directions［J］.Ther Adv Med Oncol,2018,10:1758835918786451.
［22］　WEISE A,DNKER N.High trefoil factor 1 (TFF1) expression in human retinoblastoma cells correlates with low growth kinetics,increased cyclin-dependent kinase (CDK) inhibitor levels and a selective down-regulation of CDK6［J］.Histochem Cell Biol,2013,139(2):323-338.
［23］　WU Q,SUN X,ZHENG G.VEGF overexpression is associated with optic nerve involvement and differentiation of retinoblastoma:a PRISMA-compliant meta-analysis ［J］.Medicine,2018,97(51):e13753.
［24］　RAMREZ J S,ROMERO M B,DAZ Y M,BERNAL F H,AVILA M A.Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?［J］.BMC Res Notes,2019,12(1):323.
［25］　LAMB L S,SIM H W,MCCORMACK A I.Exploring the role of novel medical therapies for aggressive pituitary tumors:a review of the literature-“are we there yet?”［J］.Cancers,2020,12(2):308.
［26］　HOSAKA K,YANG Y,SEKI T,DU Q,JING X,HE X,et al.Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors［J］.Nat Commun,2020,11(1):3704.
［27］　KELLISH P,SHABASHVILI D,RAHMAN M M,NAWAB A,GUIJARRO M V,ZHANG M,et al.Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival［J］.J Clin Invest,2019,129(6):2279-2292.
［28］　JOUNAIDI Y,DOLOFF J C,WAXMAN D J.Conditionally replicating adenoviruses for cancer treatment［J］.Curr Cancer Drug Targets,2007,7(3):285-301.
［29］　BURG V D,SJOERD H.Correlates of immune and clinical activity of novel cancer vaccines［J］.Semin Immunol,2018:39:119-136.
［30］　LOPES A,VANDERMEULEN G,PRAT V.Cancer DNA vaccines:current preclinical and clinical developments and future perspectives［J］.BioMed Central,2019,38(1):146.
［31］　DUPERRET E K,TRAUTZ A,AMMONS D,PERALES-PUCHALT A,WISE M C,YAN J,et al.Alteration of the tumor stroma using a consensus DNA vaccine targeting fibroblast activation protein (FAP) synergizes with anti-tumor vaccine therapy in mice ［J］.Clin Cancer Res,2018,24(5):1190-1201.
［32］　CACCIAVILLANO W,SAMPOR C,VENIER C,GABRI M R,DE DVILA M T.A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies［J］.Ped Blood Cancer,2015,62(12):2120-2124.
［33］　AXELROD M L,COOK R S,JOHNSON D B,BALKO J M.Biological consequences of MHC-II expression by tumor cells in cancer［J］.Clin Cancer Res,2019,25(8):2392-2402.

相似文献/References:

[1]刘瑾 朱豫.视网膜母细胞瘤的治疗进展[J].眼科新进展,2013,33(1):000.
[2]常海敏 杨磊 千新来.Calphostin C对人视网膜母细胞瘤细胞增殖的抑制作用[J].眼科新进展,2013,33(9):000.
[3]崔平 南娜 康洁 李军会 申景然.白藜芦醇对人视网膜母细胞瘤细胞侵袭能力的影响及机制研究[J].眼科新进展,2012,32(1):000.
[4]宋念艺 陈绪涛 张娴.B超、CT及MRI检查在视网膜母细胞瘤诊断中的价值[J].眼科新进展,2012,32(10):000.
[5]张千帆 刘瑞敏 穆红梅 郭洋 申飞 刘莹.白藜芦醇对视网膜母细胞瘤Y79细胞增殖的影响及其机制[J].眼科新进展,2012,32(11):000.
[6]兰兰 惠延年 曾光伟.微小RNA与磷酸化胞外信号调节激酶在视网膜母细胞瘤中的表达及其相关性分析[J].眼科新进展,2013,33(6):000.
[7]覃冬菊,唐罗生,游庆华,等.HSP27、增殖细胞核抗原在视网膜母细胞瘤中的表达[J].眼科新进展,2010,30(5):000.
[8]蒋永强 吴晓梅 连金贤.视网膜母细胞瘤术后23 a未复发1例[J].眼科新进展,2009,29(1):000.
[9]陈雪 李海平 张培 曹安民. 小胶质细胞在视网膜母细胞瘤中的活化及分布研究[J].眼科新进展,2014,34(1):029.
[10]孙燕 张煦 王登廷 祝杰 郑吉琦. Livin、PTEN及MMP-9在视网膜母细胞瘤中的表达及相关性研究[J].眼科新进展,2014,34(2):135.

备注/Memo

备注/Memo:
国家自然科学基金项目 (编号：81671741)
更新日期/Last Update: 2021-09-05